- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
This study is testing a new tablet, AP1189, for people recently diagnosed with rheumatoid arthritis who haven't tried other strong medicines yet. It aims to see how well different doses of AP1189 lower inflammation and improve symptoms when taken with another common arthritis medicine.
For: Rheumatoid ArthritisBulgaria · Czechia · Poland - AuthorisedTherapeutic exploratory (Phase II)
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
This study looks at new ways to decide when to start a second treatment for certain types of lymphoma, using a blood test. It aims to see if this approach is safe and effective in helping patients.
For: Diffuse large B-cell lymphomas (DLBCL · Diffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCL · High-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiationPoland - Ongoing, recruitingTherapeutic use (Phase IV)
Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy
This study looks at treating an irregular heartbeat called atrial fibrillation (AF) early in people with a heart condition called hypertrophic cardiomyopathy (HCM). It's trying to find out if early treatment of AF helps prevent serious health issues like stroke or further heart problems.
For: Hypertrophic cardiomyopathy (HCM) is the most common genetically determined disease of the heart · characterized by a varied picture and clinical course. The first comprehensive clinical description of the disease comes from the 1960s. Currently · the disease is diagnosed on the basis of a phenotypic picture showing left ventricular hypertrophyPoland - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
An Open-label, Randomized, Three-period, Crossover Study to compare the Pharmacokinetics of GB1211 upon dosing a capsule under fasting condition and a tablet under fasting and fed conditions in healthy volunteers.
This study is testing a new medicine in healthy volunteers. It looks at how the body handles the medicine when given in different forms (capsule or tablet) and with or without food. The aim is to understand how the medicine behaves in the body.
For: Non-small Cell Lung Cancer · Advanced liver Fibrosis and CirrhosisNetherlands - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).
This study looks at a new drug, GB1211, combined with an existing one, atezolizumab (Tecentriq), for non-small cell lung cancer. Researchers want to see if this combination is safe and how well it works to shrink tumours or stop them from growing. It involves different study parts.
For: Study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC). · Study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).France · Spain - AuthorisedTherapeutic use (Phase IV)
Diagnosing Vesicoureteric Reflux in Children by Direct Isotope Cystography and Contrast Enhanced Voiding Ultrasonography
This study is looking for better ways to find out if children have vesicoureteral reflux (VUR). VUR is when urine flows the wrong way back up towards the kidneys. They are comparing two different types of scans to see which one works best.
For: Vesicoureteral refluxFinland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome (LevoTako Trial)
The LevoTako trial looks at a medicine called Levosimendan for people with a temporary heart condition called Takotsubo Syndrome. It's a large study to see if this medicine helps the heart recover faster while in the hospital.
For: Takotsubo syndromePoland